Answer
The mean terminal half-life of enzalutamide after a single oral dose in patients with prostate cancer is 5.8 days (range 2.8–10.2 days).
Sources for this answer
- Enzalutamide Astellas 40 mg film coated tablets (Great Britain)Astellas Pharma Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 11Document updated
Sources checked